Psychological Medicine
November 1, 2024
L. Roldán, Teresa Sánchez‐Gutiérrez, I. Fernández-Arias et al.
Background Cannabis use and familial vulnerability to psychosis have been associated with social cognition deficits. This study examined the potential relationship between cannabis use and cognitive biases underlying social cognition and functioning in patients with first episode psychosis (FEP), their siblings, and controls. Methods We analyzed a sample of 543 participants with FEP, 203...
Psychological Medicine
May 9, 2024
J. Selten, Marta Di Forti, Diego Quattrone et al.
BACKGROUND We examined whether cannabis use contributes to the increased risk of psychotic disorder for non-western minorities in Europe. METHODS We used data from the EU-GEI study (collected at sites in Spain, Italy, France, the United Kingdom, and the Netherlands) on 825 first-episode patients and 1026 controls. We estimated the odds ratio (OR) of psychotic disorder for several groups of...
Psychological Medicine
May 4, 2023
Giulia Trotta, Victoria Rodriguez, Diego Quattrone et al.
Abstract Background Childhood adversity and cannabis use are considered independent risk factors for psychosis, but whether different patterns of cannabis use may be acting as mediator between adversity and psychotic disorders has not yet been explored. The aim of this study is to examine whether cannabis use mediates the relationship between childhood adversity and psychosis. Methods Data were...
Psychological Medicine
May 2, 2023
Edoardo Spinazzola, Diego Quattrone, Victoria Rodriguez et al.
Abstract Background While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis. Methods We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case–control study. 558 first-episode psychosis patients (FEPp) and 567...
Translational Psychiatry
August 10, 2021
Diego Quattrone, Ulrich Reininghaus, Anne Richards et al.
Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms...
Translational Psychiatry
May 12, 2020
Chandni Hindocha, Diego Quattrone, Tom P. Freeman et al.
Epidemiological and biological evidence support the association between heavy cannabis use and psychosis. However, it is unclear which cannabis users are susceptible to its psychotogenic effect. Therefore, understanding genetic factors contributing to this relationship might prove an important strategy to identify the mechanisms underlying cannabis-associated psychotic experiences. We aimed to...
The Lancet Psychiatry
May 1, 2019
Marta Di Forti, Diego Quattrone, Tom P. Freeman et al.
Summary Background Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder....
Schizophrenia Bulletin
April 1, 2018
Marta Di Forti, Diego Quattrone, Giada Tripoli et al.
Abstract Background Cannabis use remains the most widely used recreational drug worldwide. Following from several USA states legalisation policies, European countries are reconsidering their cannabis laws. While a significant amount of Epidemiological evidence has reported that cannabis use increases the risk of psychosis it is still unclear: 1) what underpins individual differences in...
Drug and Alcohol Dependence
November 1, 2010
Bradley Platt, Sunjeev K. Kamboj, C. Morgan et al.
BACKGROUND While heavy cannabis-users seem to show various cognitive impairments, it remains unclear whether they also experience significant deficits in affective functioning. Evidence of such deficits may contribute to our understanding of the interpersonal difficulties in cannabis-users, and the link between cannabis-use and psychological disorders (Moore et al., 2007). METHOD Emotion...
European Psychiatry
2009
C. Morgan
Cannabis contains a myriad of different chemicals, more than 60 of which are unique to the plant and called cannabinoids. The main psychoactive ingredient is delta9-tetrahydrocannabinol (THC) and this produces the effects that users seek (Curran et al., 2002 Psychopharmacology 164: 61-70). When given intravenously to healthy humans, THC produces psychotic-like and anxiogenic effects (D’Souza et...